Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Evonetix raises $30m for desktop gene synthesis tech

By Sean Whooley | March 2, 2020

Evonetix announced today that it closed a $30 million Series B funding round as it develops technology for enabling gene synthesis on a chip.

The Cambridge, U.K.-based synthetic biology company said the funding round, led by new investor Foresite Capital, is slated to fund the company through to the introduction of its desktop DNA platform, according to a news release. Existing investors Draper Espirit, DCVC, The Morningside Group, Providence Investment Company, Cambridge Consultants, Rising Tide Fund and Civilization Ventures also participated in the financing.

Evonetix’s DNA platform is designed to facilitate and enable synthetic biology with applications across industries like healthcare, pharma, biotech, food, agriculture and data storage. The silicon chip, made by microelectromechanical systems (MEMS) processing, is supposed to control the synthesis of DNA at thousands of independently controlled reaction sites or “pixels” on the chip surface. After synthesizing, strands are then assembled on-chip into double-stranded DNA in a process designed to identify and remove errors to enable accuracy, scale and speed.

The company, founded in 2015, previously closed a $12.3 million Series A round in 2018, according to the news release. Founded by Cambridge Consultants and Providence Investment Company and backed by venture capitalist Hermann Hauser, Evonetix has now raised $46 million to date.

“The backing of both our existing and new investors will enable us to fast-track development, testing and delivery of our highly parallel desktop platform, which will be available to every researcher to accelerate their ability to use biology on a scale not possible with existing approaches,” Evonetix CEO Tim Brears said in the news release.

“The next set of breakthroughs in healthcare and synthetic biology will come from technologies that can go beyond reading DNA to writing it,” added Draper Espirit venture partner Vishal Gulati. “Evonetix is leveraging the UK’s strength in DNA research to build this unique, ground-breaking DNA synthesis platform. We’re excited to welcome Foresite Capital, one of the world’s leading life-sciences investors, to support this company to achieve the next stage of its growth and look forward to working closely with this talented team.”


Filed Under: Genomics/Proteomics
Tagged With: Evonetix
 

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Related Articles Read More >

Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE